Galmed Pharmaceuticals Ltd (GLMD) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access GLMD Annual Income Statement →
Reviewing income statement figures over time helps illustrate how Galmed Pharmaceuticals Ltd generates earnings and manages operating expenses.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing3.64
Research and Development Expense4.87
Other Operating Expense / -Income0.00
Total operating costs including COS8.51
Operating income / -loss-8.51
Net Interest Expense / -Income0.00
Other loss / -income-18.82
Total costs & expenses-10.31
Income & Taxes
Income / -loss before income taxes10.31
Income after income taxes10.31
Income / -loss from continuing operations-4.82
Net income / -loss1.40
Income / -loss to shareholder-4.82
EBIT10.31
EBITD10.31
EBITDA10.32
Earnings Per Share
Basic EPS (excl. extra items)-8.96
Basic Net EPS-8.96
Basic shares outstanding (Mill. of Units)0.54
Diluted Net EPS-8.96
Diluted average shares (Mill. of Units)0.54
4 historic quarters locked

Sign in to unlock the full Galmed Pharmaceuticals Ltd income statement history.

About GLMD Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.